Silence Therapeutics (NASDAQ:SLN) Hits New 12-Month High at $26.74

Silence Therapeutics plc (NASDAQ:SLNGet Free Report)’s stock price reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $26.74 and last traded at $26.15, with a volume of 7131 shares traded. The stock had previously closed at $26.25.

Analysts Set New Price Targets

A number of brokerages recently issued reports on SLN. BMO Capital Markets began coverage on Silence Therapeutics in a research report on Wednesday, January 31st. They issued an “outperform” rating and a $67.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research report on Thursday, February 22nd.

Get Our Latest Stock Report on Silence Therapeutics

Silence Therapeutics Trading Down 3.4 %

The company has a debt-to-equity ratio of 0.01, a current ratio of 4.86 and a quick ratio of 4.86. The stock has a 50 day moving average of $20.85 and a 200 day moving average of $14.13.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Artal Group S.A. grew its stake in shares of Silence Therapeutics by 236.6% during the second quarter. Artal Group S.A. now owns 1,700,000 shares of the company’s stock valued at $9,350,000 after buying an additional 1,194,926 shares during the last quarter. Vivo Capital LLC bought a new stake in shares of Silence Therapeutics in the fourth quarter worth about $8,862,000. Lynx1 Capital Management LP bought a new stake in shares of Silence Therapeutics in the third quarter worth about $2,315,000. M28 Capital Management LP grew its stake in shares of Silence Therapeutics by 149.3% in the second quarter. M28 Capital Management LP now owns 363,800 shares of the company’s stock worth $2,001,000 after purchasing an additional 217,900 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of Silence Therapeutics by 27.1% in the first quarter. Goldman Sachs Group Inc. now owns 965,815 shares of the company’s stock worth $18,350,000 after purchasing an additional 205,815 shares during the last quarter. Institutional investors own 64.27% of the company’s stock.

Silence Therapeutics Company Profile

(Get Free Report)

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's mRNAi GOLD GalNAc Oligonucleotide Discovery platform that is used to target specific disease-associated genes in the liver.

Recommended Stories

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.